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The accumulation of redox-active transition metals in the brain and metal
dyshomeostasis are thought to be associated with the etiology and pathogenesis
of several neurodegenerative diseases, and Alzheimer’s disease (AD) in particular.
As well, distinct biometal imaging and role of metal uptake transporters are
central to understanding AD pathogenesis and aging but remain elusive, due
inappropriate detection methods. We therefore hypothesized that Octodon degus
develop neuropathological abnormalities in the distribution of redox active biometals,
and this effect may be due to alterations in the expression of lysosomal protein,
major Fe/Cu transporters, and selected Zn transporters (ZnTs and ZIPs). Herein, we
report the distribution profile of biometals in the aged brain of the endemic Chilean
rodent O. degus—a natural model to investigate the role of metals on the onset and
progression of AD. Using laser ablation inductively coupled plasma mass spectrometry,
our quantitative images of biometals (Fe, Ca, Zn, Cu, and Al) appear significantly
elevated in the aged O. degus and show an age-dependent rise. The metals Fe, Ca, Zn,
and Cu were specifically enriched in the cortex and hippocampus, which are the regions
where amyloid plaques, tau phosphorylation and glial alterations are most commonly
reported, whilst Al was enriched in the hippocampus alone. Using whole brain extracts,
age-related deregulation of metal trafficking pathways was also observed in O. degus.
More specifically, we observed impaired lysosomal function, demonstrated by increased
cathepsin D protein expression. An age-related reduction in the expression of subunit
B2 of V-ATPase, and significant increases in amyloid beta peptide 42 (Aβ42), and
the metal transporter ATP13a2 were also observed. Although the protein expression
levels of the zinc transporters, ZnT (1,3,4,6, and 7), and ZIP7,8 and ZIP14 increased
in the brain of aged O. degus, ZnT10, decreased. Although no significant age-related
change was observed for the major iron/copper regulator IRP2, we did find a significant
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increase in the expression of DMT1, a major transporter of divalent metal species,
5′-aminolevulinate synthase 2 (ALAS2), and the proto-oncogene, FOS. Collectively, our
data indicate that transition metals may be enriched with age in the brains of O. degus,
and metal dyshomeostasis in specific brain regions is age-related.
Keywords: LA-ICPMS, metals, Alzheimer’s disease, bioimaging, Octodon degus
INTRODUCTION
Alzheimer’s disease (AD) is the most common progressive age-
related neurodegenerative disorder, characterized by debilitating
effects on brain function, such as memory loss and decline in
cognitive abilities ultimately resulting in loss of independent
functioning (Teri et al., 1989; Baddeley et al., 1991; Terry
et al., 1991). The two major pathological hallmarks of AD are
extracellular amyloid plaques composed of insoluble amyloid
beta (Aβ) protein, and intra-neuronal neurofibrillary tangles
(NFTs) containing hyperphosphorylated tau (Khachaturian,
1985; Joachim et al., 1987; Selkoe et al., 1987; Mirra et al.,
1991; Brun and Englund, 2002). While a substantial body of
evidence has implicated neuroinflammation, oxidative stress,
excitotoxicity, and oligomeric Aβ toxicity as AD contributing
factors, the precise mechanism of AD etiopathology remains
unclear (Halliwell, 1989). Several studies have shown that
dysregulated transition metal metabolism, particularly Cu, Fe,
and Zn may be casually linked to the neuropathology of AD, and
may enhance Aβ aggregation and toxicity (Bush, 2003; Bush et al.,
2003; Finefrock et al., 2003).
Over the last two decades, several studies using clinical
diagnosis and post-mortem AD brain tissue have shown that
the levels of Cu, Fe, and Zn accumulate in large concentrations
within Aβ plaques (Lovell et al., 1998). Moreover, it has been
demonstrated that Cu, Fe, and Zn are associated with the
metabolism and functional roles of Aβ and amyloid precursor
protein (APP; Smith et al., 2007). This has led to the hypothesis
that abnormal biometal deposition may play an important role
in the pathobiology of AD, and metal chelation may represent
an important therapeutic strategy to prevent the onset or slow
down the progression of AD (Bush, 2003; Faux et al., 2010;
Bonda et al., 2011; Braidy et al., 2014). Levels of Cu and Fe
are upregulated in the brain with age, suggesting that an age-
dependent increase in bioactive transition metals may contribute
to AD pathology (Maynard et al., 2002). However, the anatomical
distribution of these metals within the brain remains unclear.
The latter is important for further etiological exploration and the
development of agents for the treatment and management of AD.
Apart from the involvement of Cu and Fe, Zn may also
play a critical role in the pathogenesis of AD, although
the exact mechanism remains unclear (Graham et al., 2014;
Hancock et al., 2014; McCord and Aizenman, 2014; Rembach
et al., 2014; Yuan et al., 2014). The transcription of APP is
mediated by Zn-dependent transcription factors, Sp1 and NF-κB
(Borchardt et al., 2000). Zn has also been shown to facilitate
the oligomerization of Aβ (Taddeo et al., 2014). Furthermore,
cleavage of APP by the protease α-secretase is inhibited by
Zn (Parvathy et al., 2000). Therefore, it is highly likely that
dysregulation of Zn may be involved in AD (Watt et al.,
2014). The levels of Zn in brain tissue are modulated by
two main families of Zn transporters; ZnTs (zinc transporters)
and ZIPs (Zrt/Irt-like protein, SLC39). Briefly, the intracellular
uptake of Zn by neurons is mediated by ZIP protein, and
through activated Ca2+ voltage gated ion channels, α-amino-
3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptors,
and N-methyl-D-aspartate (NMDA) receptors (Sensi et al., 2009).
The export of zinc extracellularly, or from the cytosol to the
lumen of intracellular organelles is mediated by ZnTs. Although
several Zn transporters have previously been investigated in
several AD models, a more comprehensive study is warranted
(Sensi et al., 2009), especially in natural models which are likely
more representative of late onset AD.
Several in vitro and in vivo models have been developed,
the most commonly used being transgenic mice models (Braidy
et al., 2012). However, due to the high complexity of AD
pathology, transgenic mice models recapitulate many, but not
all, of the major features of AD, and their validity for the
sporadic form of AD is questionable (Braidy et al., 2012). In
this context, the establishment and validation of a wild-type
“natural” animal model of AD, which recapitulates the neuronal,
neuropathological, and behavioral abnormalities of sporadic or
late-onset AD, and is small and easy to handle, would be of great
benefit.
Previous studies from our laboratory have identified the
Octodon degus, a South American rodent endemic to Central
Chile, as a “natural” rodent model for AD (Inestrosa et al.,
2005). The O. degus is a diurnal, visual, and highly social rodent
that “naturally” develops several symptoms that can be linked
to the neuropathology of AD. This caviomorph rodent lives up
to an average of 7 years in captivity, making it an interesting
model for use in longitudinal studies, including those related
to the neurobiology of AD (Colonnello et al., 2011; Uekita
and Okanoya, 2011). The amino acid sequence of wild-type
O. degus Aβ shares a high degree (97.5%) of genetic homology
with humans (Inestrosa et al., 2005; Braidy et al., 2012). It
was recently reported that age-relate changes in Aβ oligomers
and tau phosphorylation in O. degus correlated with a decrease
in both spatial and object recognition memory, and impaired
postsynaptic and neural plasticity (Ardiles et al., 2012). However,
changes in the levels and spatial distribution of Cu, Zn, and Fe,
and other redox-active metals in the aged O. degus brain tissue
are of particular interest.
In this study, we aim to further examine the homology
between Alzheimer-type pathology in the South American
rodent O. degus and sporadic AD in humans by studying the
neuropathological abnormalities in the animal to determine
if it is indeed a unique “natural” model for the study of
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the pathobiology of AD. We hypothesized that: (1) O. degus
develop neuropathological abnormalities in the distribution of
redox active biometals, such as Fe, Ca, Zn, Cu, and Al; (2)
lysosomal markers are affected in the “natural” model, similar to
human AD; (3) altered biometal trafficking pathways, including
major Fe/Cu regulatory genes, selected ZnTs, and ZIPs may
represent a potential mechanism for altered distribution of these
biometals in brain sections across the entire life-cycle of the
O. degus. To address these hypotheses, we quantitatively imaged
the anatomical distribution of Cu, Fe, Zn, Ca, and Al, in the
brains of aged O. degus by a laser ablation inductively coupled
plasma (ICP) system using mass spectrometry (LA-ICPMS). We
have delineated regions of interest (ROIs) and determined the
biometal concentrations in the O. degus brain with advanced
age. Using western blotting, we also investigated potential
mechanisms for these changes by examining the expression
of biometal trafficking pathways, including lysosomal function,
major Fe/Cu regulatory genes, and selected ZnTs and ZIPs.
MATERIALS AND METHODS
Animals
Octodon degus were obtained from a breeding colony at the
animal facility of the University of Valparaiso and maintained
in a controlled temperature room (23 ± 1◦C), under a 12:12 h
light/dark cycle, with water and food provided ad libitum. At the
time of this study, 16 male O. degus were grouped by age, from
12 to 36 months of age (n = 8 per group). Ages were selected
to represent the development of AD-like pathology (36 months).
All efforts were made to minimize animal discomfort and stress
while also limiting the number of animals used. Aged animals
were anesthetized with Equitesin (2.5 ml/kg, i.p.) and injected
with heparin (4 USP/kg, i.p.). Afterward, brains were surgically
removed from their skulls and frozen in isopentane at −78.5◦C.
All procedures were conducted according to animal protocols
approved by the Institutional Animal Care and Use Committee
at the University of Valparaiso and Pontifical Catholic University
of Chile.
Sample Preparation for LA-ICPMS
Cryosections of brains of 10 µm thickness were mounted
on silanized slides. Neighboring sections were stained with
hematoxylin and eosin staining.
LA-ICPMS Instrumentation
LA-ICPMS was performed using a NewWave NWR213 (New
Wave UP 266, New Wave, Fremont, CA, USA) laser ablation
pulsed laser sampling accessory connected to a PerkinElmer
Nexion ICPMS. The material was ablated using a focused
Nd:YAG laser and then transported by argon as carrier gas into
the ICP plume. Following ion formation in the ICP ion source,
the positively charged ions were extracted from the argon plasma
(at≈100 kPa) via the differentially pumped interface (at≈130 Pa)
between the sampler and skimmer cones into the high vacuum of
the quadrupole mass analyzer, and were separated with respect
to their mass-to-charge ratios and detected by the ion detector.
The experimental parameters of LA-ICPMS were optimized with
respect to the maximum ion intensity of 63Cu+ using a well-
homogenized synthetic laboratory standard. Tissue was ablated
using a laser setting of 25% of maximum power, with a repetition
rate of 20 Hz, a laser spot size of 50 µm, and a scan speed of
25. The gas flows in the LA-sample chamber were 0.85 l/m for
He, and 0.65 l/m for Ar. Elemental analysis on the ICPMS was
performed using peak hopping scan mode, with a dwell time of
90.7 ms per amu, and an integration time of 24,048 ms. All mass
spectrometric measurements were performed with established
protocols in routine mode in Becker’s BrainMet Laboratory
(BrainMet–Bioimaging of Metals in Brain and Metallomics) at
Forschungszentrum Jülich. Optimized experimental parameters
have been previously described (Matusch et al., 2010). Instrument
response was calibrated using the NIST 614 and NIST 612
standards to produce images of the change in elemental
distribution across the tissue. Image data was processed and
calibrated using the IOLITE software, then rendered as color
images using MATLAB.
Hematoxylin and Eosin Staining
Slides were over-stained with hematoxylin for 10 min and excess
stain was removed by running under tap water for 2 min.
Afterward, they were differentiated and destained by submerging
in acid alcohol for a few seconds until sections appeared red then
rinsed briefly under tap water to remove acid. Slides were blued in
bicarbonate until nuclei stood out significantly then rinsed under
tap water for 5 min. Afterward, the slides were submerged in
70% ethanol for 3 min, and then in eosin for 2 min. The slides
were then taken through three changes of 95% ethanol, for 5 min
each. Finally, slides were rinsed in 100% ethanol, coverslipped
and mounted.
Western Blotting
Octodon degus brains were dissected on ice and immediately
processed. Briefly, cortical tissue was homogenized in
radioimmunoprecipitation assay buffer (RIPA buffer)
[50 mM, Tris–Cl, pH 7.5, 150 mM NaCl, 1% NP-40, 0.5%
sodium deoxycholate, and 1% sodium dodecyl sulfate (SDS)],
supplemented with a protease inhibitor cocktail (Sigma-Aldrich
P8340) and phosphatase inhibitors (50 mM NaF, 1 mM Na3VO4,
and 30 µM Na4P207), using a Potter homogenizer and then
passed sequentially through different caliber syringes. Protein
samples were centrifuged at 14,000 rpm at 4◦C twice for
15 min. Total protein concentration was determined using the
BCA Protein Assay Kit (Pierce Biotechnology, Rockford, IL,
USA). Hippocampal samples (20 µg) were resolved by 10%
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) and transferred to a polyvinylidene difluoride (PVDF)
membrane The incubation with a primary antibody; then a
secondary anti-goat peroxidase conjugated antibody (Pierce) was
used and developed using an ECL kit (Western Lightning Plus
ECL, PerkinElmer) following the manufacturer’s instructions.
Statistical Analysis
To validate the metal ion images (Figure 1) and quantify
the levels of Cu, Fe, Zn, Ca, and Al in the hippocampus
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FIGURE 1 | LA-ICPMS imaging of Cu, Fe, Zn, Ca, and Al, in whole brain, sagittal sections of O. degus with age. H&E stained histological sections are
shown on the far left, and neighboring brain sections were used for LA-ICPMS of each of five metals.
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FIGURE 2 | (A) Quantitative alteration of Cu, Fe, Zn, Ca, and Al in the hippocampus of O. degus with age. Significant difference between 1- and 3-year-old
O. degus. ∗p < 0.05. (B) Table of absolute values mean ± SEM.
(Figure 2) and cortex (Figure 3) of O. degus with age, two-
dimensional images were first acquired as previously described
by da Silva and Arruda (2013). The raw data that was collected
from the IOLITE software were exported as Microsoft Excel
files, and each line that was formed by ablation was exported
to a different worksheet. A total of 60 lines were required for
mapping the entire slide surface. Therefore, 60 IOLITE files
were generated, and each one was exported to a new worksheet,
culminating in 60 Excel worksheets. Each worksheet contained
the results of the analyte values on the entire slide surface.
Blanks were added to account for the argon atmosphere where
there was no ablation, and the blank signal was subtracted from
the sample signal. The results were normalized using 13C as
an internal standard. The average net 13C ion intensity was
used as a surrogate of slice thickness, and calculated from
histograms of pixel values (Becker et al., 2012). Afterward,
excel files were converted into a text file to generate an image
using MATLAB. The MATLAB image was generated using
(x, y) coordinates. The x data set were collected from the
LA-ICPMS, and the y data set was based on the number of
lines. The z value representing the relative intensity at each
point was correlated with the x and y matrix plane. For the
x-axis, the ICP-MS acquisition time was considered, and LA
system scan speed were used. For the y-axis, the spacing among
the lines was used. Finally, data were converted into a matrix
plane (x, y) in MATLAB. For data acquisition, a transpose
function (w = z′) was used to adjust the image, and maintain
relative intensity at each point. MATLAB images were saved
as 8 bit grayscale TIFFs and were corrected for linear drift
(factor of 1 was used at the end of the sample next to the
standard, and the correction factor progressively increased or
decreased line by line toward the other end) using IMAGENA
(Osterholt et al., 2011). The hippocampus and cortex, including
glass background and entire section trace metal concentrations
were calculated from ion intensities averaged from freely drawn
ROIs (representing the location of the hippocampus and cortex,
respectively) within ion intensity images using PMOD version
3.01. This was repeated four times per sample to ensure
greater reliability and accuracy of data. Microphotographs
obtained prior to ablation and the RB4 Watson Paxinos
1www.pmod.com
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FIGURE 3 | (A) Quantitative alteration of Cu, Fe, Zn, Ca, and Al in the frontal cortex of O. degus with age. Significant difference between 1- and 3-year-old O. degus.
∗p < 0.05. (B) Table of absolute values mean ± SEM.
Atlas2 were used to neuroanatomically define ROIs. Standard
measurements were processed using Microsoft Excel algorithm
calculating slope of the calibration curve. Data were analyzed
based on concentration = (maximum counts − minimum
counts) × (ion intensity-background)/(255 × slope). Results
were expressed as mean ± standard error over the 5 vs
4 individual averages of regional element concentrations
using Prism software (GraphPad Software Inc.). The classical
Bonferroni threshold for 4 regions × 5 elements was p = 0.008.
For the Holmes modified Bonferroni correction, a p-value of
≤0.05 was considered to be statistically significant for the
first region, for the second 0.05/2, for the third 0.05/3 and
so on.
Western blots (Figures 4–7), were quantified using ImageJ
1.47v (NIH; Rasband, W.S., ImageJ, U. S. National Institutes of
Health, Bethesda, MD, USA3, 1997–2010). Statistical analysis was
2http://www.callisto-science.org/NSI/Neuroscience_Image_Database/RUN_
RBSC.PDF
3http://imagej.nih.gov/ij
performed using Prism software (GraphPad Software Inc.). Data
were analyzed using the Student’s t-test, and the post hoc Tukey’s
multiple comparison test was applied. A p-value of ≤0.05 was
considered to be statistically significant.
RESULTS
Microdistribution of Cu, Fe, Zn, Ca, and
Al, in Whole Brain Sections of O. degus
as a Natural Model of Aging and AD
Progression
Biometal accumulation can only be examined in humans using
post-mortem brain sections collected at the end stage of the
disease, and the distribution of redox-active brain-metals during
the pathobiology of AD remains unclear. By using the O. degus—
a natural model for AD—dyshomeostasis in Cu, Fe, Zn, Ca, and
Al distribution can be examined in various brain regions with age
(from 1 to 3 years old) and AD progression (from early stage
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FIGURE 4 | Evidence for lysosomal aberrations in the frontal cortex with age. (A) Altered levels of cathepsin D, V-ATPase, Aβ42, ATP13a2 were observed in
the brain at 3 years of age compared to 1-year-old O. degus. The blots shown are representative data from an experiment repeated eight times. (B) Graphs are
mean ± SEM brains from brains of eight O. degus for each age group. Significantly different ∗p < 0.01 compared to 1-year-old O. degus. (C) Table of absolute
values mean ± SEM.
to late stage). Brain section elemental images are presented in
Figure 1. These images were used for metals quantification in the
brain regions of hippocampus and cortex (Figures 2, 3).
Several studies have shown that Cu is highly abundant in
plaques but is present at lower than the limits of detection, in
the whole brain of AD (Burdo and Connor, 2003; Bush, 2003;
Feaga et al., 2011). Our Cu images in Figure 1 show that the
amount of Cu in the brain of O. degus increases with age. These
increases are focused in the hippocampal and cortical regions of
O. degus. Figure 2 shows that Cu in the hippocampus of O. degus
significantly increased with age, from 10.1 µg g−1 at 1 year of age
to 52.1 µg g−1 at 3 years of age. Comparatively, an increase in the
Cu level (21–65 µg g−1) was found in cortex from 1 to 3 years of
age. Our imaging data suggests that Cu is enriched in the aging
brain, and to a greater extent in the AD brain.
Similarly, Fe levels are increased with age in the brain of
O. degus, indicating that, like Cu, Fe is an age-dependent enriched
element in the brain (Figure 1). Fe was found to be increased
in the hippocampus and cortex. The content of Fe in the
hippocampus of 3 years old O. degus was in the range of 15–25
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µg g−1, which was significantly higher than young O. degus
(10–15 µg g−1). Figure 3 also shows an obvious Fe increase
in the cortex of O. degus with age. The Fe content in the
cortex of 3-year-old O. degus was about 90–100 µg g−1, which
was considerably higher than that of the 1-year-old O. degus
(10–15 µg g−1).
The dysregulation of Zn in AD pathology is also of major
interest (Watt et al., 2014). Our quantitative images of Zn in this
study show the cortex and hippocampus are Zn-rich regions in
brain Figure 1. The average content of Zn in the hippocampus
was 10–15 µg g−1 and did not significantly increase with age.
However, in the cortex, the content of Zn increased significantly
with age, from∼10 µg g−1 in 1-year-old O. degus, to∼80 µg g−1
in 3-year-old O. degus (Figures 1, 2).
Ca represents another important metal that plays a
fundamental role in normal brain cell function (Chen and
Nguyen, 2014). The level of Ca was found to increase with
age throughout the brain (Figure 1), and in the hippocampus
and cortex in particular, supporting the hypothesis of the
imbalance of calcium homeostasis and disturbed Ca flux in brain
components in the development of AD.
A link between Al and AD has also been the subject of
scientific debate for several decades (Andrasi et al., 1995; De
Sole et al., 2013). No significant increase in the levels of Al
was observed in the hippocampus in our study. However, Al
levels increased significantly in the cortex of aged O. degus, from
∼20 µg g−1 in 1-year-old O. degus, to ∼40 µg g−1 in 3-year-old
O. degus.
Impaired Lysosomal Function in
O. degus
Lysosomal dysfunction, has previously been reported in AD
and several transgenic rodent models (Armstrong et al., 2014;
Coffey et al., 2014; Xue et al., 2014). In frontal cortex, we
found an age-dependent increase in cathepsin D activity from
1 to 3 years of age (Figure 4). An age-dependent reduction
of subunit B2 of V-ATPase was also observed in the frontal
cortex, the site of neuropathological changes in AD, suggestive
of lysosomal impairment. We also examined the levels of Aβ
peptide Aβ42, and the metal transporter, ATP13a2. Significantly
increased concentrations of Aβ42, and decreased ATP13a2 levels
were also observed after onset of neurological disease (Figure 4),
providing further support for a relationship between AD and
lysosomal aberrations.
IRP2, DMT1, ALAS2, and FOS expression
in O. degus
To evaluate the biological significance of increased Cu and Fe
with age, we measured the protein expression of IRP2 and
DMT1 in the frontal cortex. DMT1 is a major transporter of
divalent metal species and exists in two isoforms—one that
contains an iron responsive element in the untranslated region
and would be expected to be regulated by IRP2 (DMT1-IRE)
and a second that lacks an IRE and should be regulated
independently of IRP2 levels (DMT1-non-IRE) (Wilkinson and
Pantopoulos, 2014). We found a significant increase in expression
of DMT1-non-IRE in 3-year-old O. degus compared to 1-year-old
O. degus (Figure 5). However, IRP2 protein expression remained
unchanged (Figure 5).
We also assessed the expression of additional proteins related
to Cu and Fe metabolism. The proteins of interest were
proto-oncogene c-Fos (FOS), and 5-aminolevulinate synthase
(ALAS2) (Figure 5). We found a significant increase in
expression of FOS in 3-year-old O. degus compared to 1-year-old
O. degus (Figure 5). However, the levels of ALAS2 significantly
declined with age in 3-year-old O. degus compared to 1-year-old
O. degus (Figure 5). This suggests that alterations in the ratio of
Cu and Fe significantly alter intracellular Cu/Fe pathways.
Age-Specific Alterations to Zn Transport
Pathways
Western blotting revealed age related changes in the protein
expression of Zip and ZnT metal transporter proteins.
The expression of the ER/Golgi-resident transporter, Zip7,
significantly reduced in the frontal cortex in an age-dependent
manner in 3-year-old O. degus. Similarly, significantly reduced
expression of Zip8, and Zip14 were observed in 3-year-old
O. degus (Figure 6). On the contrary, the protein expression of
ZnT1, ZnT3, ZnT4, ZnT6, and ZnT7 were significantly increased
with age in the frontal cortex of 3-year-old O. degus (Figure 7).
However, the expression of ZnT10 was significantly reduced.
Therefore, dysregulated expression of ZIP and ZnT family may
be associated with the progression and neuropathology of AD.
DISCUSSION
Natural animal models which closely resemble the
etiopathogenesis of AD are needed for research on disease
mechanisms and for drug development. No reliable “natural”
model of AD is available, and current AD research largely uses
transgenic models, which have a number of limitations, including
the fact that they do not recapitulate the morphological and
temporal patterns observed in clinical AD in humans (Braidy
et al., 2012, 2015). Therefore, data on molecular mechanisms
and drug efficacy testing using these genetically modified
models should be interpreted with care, as many previous
discoveries made in transgenic models have been lost in human
translation (Braidy et al., 2012, 2015). Spontaneous age-related
neurodegeneration reported in O. degus mimics many of
the cellular and molecular events that have been observed
extensively in experimental models and clinical AD (Inestrosa
et al., 2005, 2015; Du et al., 2015). An interesting feature of the
AD-like changes observed in O. degus brains is the fact that
they occur in aged animals and so far, have never been detected
in young animals (1-year-old; Inestrosa et al., 2015). In one
study, 3-year-old wild-type O. degus have been shown to develop
significant Aβ peptide deposition in blood vessel walls of the
brain (van Groen et al., 2011). Capillary Aβ deposition in the
cerebral cortex has been recently reported in a population-based
study of 601 individuals aged greater than 85 years, and was
associated with the severity of dementia and AD-type pathology
(Makela et al., 2016). Moreover, hippocampal tau deposits
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FIGURE 5 | Alterations in the expression of Cu/Fe metabolic protein in the frontal cortex with age. (A) Altered levels of IRP2, DMT1, ALAS2, and FOS were
reported in the brain at 3 years of age compared to 1-year-old O. degus. The blots shown are representative data from an experiment repeated eight times.
(B) Graphs are mean ± SEM brains from brains of eight O. degus for each age group. Significantly different in 3-year-old ∗p < 0.01 compared to 1-year-old
O. degus. (C) Table of absolute values mean ± SEM.
were shown to occur parallel to loss of myelin, indicative of
significant white matter degeneration in that same study (van
Groen et al., 2011). Hippocampal tau deposits have also been
detected in post-mortem AD brain tissue using THK5117,
a radiotracer for positron emission tomography (PET) scan
imaging of tau deposits (Lemoine et al., 2015). Moreover, white
matter abnormalities have been shown to not only represent an
early pathological event in AD, but may also be involved in Aβ
aggregation and tau hyperphosphorylation (Sachdev et al., 2013).
Taken together, we can postulate that amyloid and tau deposition
are age-dependent processes in O. degus, as also occurs in clinical
AD patients.
Abnormal metal deposition have also been reported in the
APP/V717I transgenic mouse model and wild-type age-matched
mice as controls using LA-ICPMS (Wang et al., 2012). However,
very few studies using LA-ICPMS as a tool for biometal analysis,
have been performed in the brain of “physiologically” aged rodent
models. One study performed demonstrated a significant increase
in Fe levels in the substantia nigra, the thalamus, and the CA1
region of the hippocampus of 14-month-old mice compared to
2-month-old mice (Becker et al., 2010). As iron is well known
to form free radicals due to its high redox active properties,
increased cerebral Fe levels may potentiate neurodegeneration.
The same study showed that the levels of Zn remained unchanged
with age. The latter supports the essential role of Zn as a major
neurotransmitter that can be stored in vesicules. Another study
showed that the global cerebral content of Cu was increased in
14-month-old mice compared to 2-month-old mice. However,
reduced Cu uptake was noted in the striatum and ventral cortex
in aged mice, which were associated with the highest decline in
cerebral superoxide dismutase-1 (SOD-1). This further suggests
that dysregulated Cu homeostasis may contribute to oxidative
stress and neurodegeneration in the aging brain (Wang et al.,
2010).
However, the current study is the first to identify specific
age-related changes in biometal trafficking and transition metal
distribution in O. degus, a potential “natural” model for AD. It is
well established that deposition of the redox elements Fe and Cu
Frontiers in Aging Neuroscience | www.frontiersin.org 9 March 2017 | Volume 9 | Article 66
fnagi-09-00066 March 27, 2017 Time: 17:44 # 10
Braidy et al. Metal Imaging in the Octodon degus
FIGURE 6 | Changes in the expression of ZIP protein in the frontal cortex with age. (A) Altered levels of ZIP7,8 and ZIP14 were reported in the brain after 3
years of age compared to 1-year-old O. degus. The blots shown are representative data from an experiment repeated eight times. (B) Graphs are mean ± SEM
brains from brains of eight O. degus for each age group. Significantly different in 3-year-old ∗p < 0.01 compared to 1-year-old O. degus. (C) Table of absolute values
mean ± SEM.
contribute to Aβ-induced toxicity in the AD brain (Lovell et al.,
1998; Bush, 2003; Bush et al., 2003; Matusch et al., 2010). Evidence
shows the redox cycling of Cu contributes to the oxidative stress
of AD (Burdo and Connor, 2003; Chen and Nguyen, 2014;
Hancock et al., 2014; McCord and Aizenman, 2014). Although
evidence for altered Cu levels in serum are conflicting, Cu has
been found to be significantly dysregulated in patients with mild
cognitive impairment (MCI) who subsequently progressed to
dementia (Mueller et al., 2012). Furthermore, the levels of Cu
have been shown to be increased with age in the hippocampus
and cortex of APP/V717I transgenic mice (Wang et al., 2012).
Moreover, the ratio of Cu/Fe as well as Cu levels may be a useful
biomarker to distinguish between progressive and cognitively
stable MCI patients (Mueller et al., 2012). This ratio is consistent
with a previous study which examined the ratio of ceruloplasmin
and transferrin (the major protein carriers of Cu and Fe,
respectively) in serum from early AD cases: ceruloplasmin was
increased while transferrin was decreased (Squitti et al., 2002).
However, an earlier study supported an increase in serum
ceruloplasmin, but challenged the decrease in serum transferrin
in AD (Molaschi et al., 1996).
We also observed a significant increase in the levels of Fe
in aged O. degus. This is in line with previous findings in the
APP/V717I transgenic mouse model, and age-matched mice
as controls using LA-ICPMS (Wang et al., 2012), suggesting
that Fe is age-dependently enriched in the brain. The increased
Fe level is likely due to the constant transportation of Fe to
the brain mediated by capillary endothelial cells, and increased
release of Fe into the blood via the blood–brain barrier (Burdo
and Connor, 2003; Burdo et al., 2003). While Fe was found
mainly enriched in the substantia nigra and corpus callosum
of APP mice (Wang et al., 2012), Fe was primarily found in
the substantia nigra and cortical area of age-matched controls.
However, several studies have shown that Fe is enriched in
plaques, and the hippocampus and frontal cortex are the main
plaque deposition regions (Burdo and Connor, 2003; Leskovjan
et al., 2009). Therefore, increased Fe content in the hippocampal
and cortical areas of the O. degus is suggestive of defective metal
transport in some micro-regions of the AD brain. Quantitative
results from a previous study using LA-ICPMS show an increased
tendency for Fe in the hippocampi of both APP and age-matched
controls, suggesting regional variations in Fe reactions in the
brain (Wang et al., 2012). The increased level of Fe in the
brain can be attributed to the presence of iron-binding proteins.
Ferritin and transferrin, represent the two-most important Fe
carriers, and are commonly found in both the white and
gray matter (Burdo et al., 1999; Thomas and Jankovic, 2004).
Therefore, accumulation of Fe may be due to the functional role
of ferritin in the brain of O. degus. Additionally, serum levels of
Fe in AD patients are inconsistent, and no study has specifically
evaluated the levels of non-heme (chelatable) iron (Mueller et al.,
2012).
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FIGURE 7 | Changes in the expression of ZnT protein in the frontal cortex with age. (A) Altered levels of ZnT1,3,4,6,7, and 10 were reported in the brain after
3-years of age compared to 1-year-old O. degus. The blots shown are representative data from an experiment repeated eight times. (B) Graphs are mean ± SEM for
brains of eight O. degus for each age group. Significance ∗p < 0.01 compared to 1-year-old O. degus. (C) Table of absolute values mean ± SEM.
As well, Zn is an important redox-active metal that plays
an important role in Aβ aggregation and extracellular plaque
formation (Watt et al., 2014). Therefore, determining the
mechanism(s) of Zn dysregulation in AD and aging is of
particular interest. The microdistribution of zinc in aged O. degus
is remarkably similar to a previous study in the APP/V717I
transgenic mouse model (Wang et al., 2012). We observed a
significant age-related increase in Zn levels in the cortex and
hippocampus, which present as Zn-enriched regions.
Additionally, Ca represents another important metal that
plays an important role in normal brain cell function (Lisek
et al., 2015). It is well established that increased Aβ can reduce
the membrane potential, thus enhancing Ca2+ influx, leading to
an accumulation of Ca2+ in cells, leading to excitotoxicity and
cell death via apoptotic processes (Greenamyre, 1991; Harkany
et al., 2000; Barger, 2004; Hynd et al., 2004; Tsai et al., 2005;
Koutsilieri and Riederer, 2007). Increased oxidative stress may
further interfere with Ca immobilization, leading to cell death via
additional cytotoxic pathways (Esposito et al., 2013; Ong et al.,
2013). It has been previously reported that Ca2+ overload can
modulate APP metabolism, and accelerate APP hydrolysis to
generate more Aβ (Wang et al., 1994; Ye et al., 2010). Our study
and others have shown that Ca increases with age in the brain,
and provides further evidence supporting the hypothesis of the
imbalance of calcium homeostasis and disturbed Ca flux in the
brain can enhance AD progression (Peterson et al., 1985, 1989;
Deary and Hendrickson, 1986; Martyn et al., 1989; Kelliher et al.,
1999; O’Day and Myre, 2004; Attems et al., 2008).
Numerous studies have shown that Al may also contribute to
the pathology of AD (Martyn, 1992; Copestake, 1993; Doll, 1993;
Kruck, 1993; Rifat, 1993; Taylor et al., 1995). A collective body of
published work indicates that: (1) Al accumulates in microtubules
and induces cortical atrophy in vivo (Garruto and Brown, 1994),
(2) Al may be involved in the formation of extracellular plaques
and NFTs (Mera, 1991; McLachlan et al., 1992; Perl, 2006); (3)
Increased incidence of AD has been observed in populations
where there are high levels of Al in drinking water supplies
(French et al., 1989; Martyn, 1992; Harrington et al., 1994; Polizzi
et al., 2002; Gupta et al., 2005; Perl, 2006); (4) Al chelators have
shown positive responses for the treatment of AD in transgenic
rodent models (Guy et al., 1991; Justin Thenmozhi et al.,
2015); and (5) Increased Al deposition is also associated with
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the pathogenesis of other neurodegenerative diseases including
Parkinson’s disease and amyotrophic lateral sclerosis (Bharathi
et al., 2008; Singla and Dhawan, 2014). While our study shows
that Al is increased with age in the cortex, no other study has
reported changes in Al distribution in the brain in other AD
models, and it is still unclear whether Al levels are elevated
in human AD patients. Thus, further studies are warranted to
elucidate the association between Al levels and AD.
The expression of cellular trafficking systems plays a critical
role in metal-induced toxicity. Abnormalities in the lysosomal
pathway have been previously reported in AD pathology, prior
to the development of NFTs or Aβ plaques (Cataldo and Nixon,
1990; Cataldo et al., 1994). Since proteolytic processing of
APP is necessary for the formation of Aβ, lysosomal proteases
have been linked with AD pathology (Vidoni et al., 2016).
The increased expression of cathepsin D reported in this
study may represent a compensatory mechanism to restore
lysosomal function (Perez et al., 2015). This is supported by
another study which showed that knockout of cathepsin D
enhances abnormal tau phosphorylation, and oxidative stress
in the brain (Khurana et al., 2010). Cathepsin D also has
an important role of maintaining neuronal homeostasis, and
optimal function of cathepsin D is therefore necessary for
the clearance of unfolded/oxidized protein that are transported
to lysosomes to facilitate their removal (Benes et al., 2008).
Similarly, vesicular ATPases are required to acidify lysosomes
and maintain an optimal acidic environment for lysosomes
(Williamson et al., 2010). One study showed that degradation or
reduced expression of V-ATPase can enhance AD pathology by
making neurons more susceptible to insult following exposure
to pathological concentrations of Aβ and tau (Williamson et al.,
2010). Therefore, the observed changes in cathepsin D and
V-ATPase may provide an additional mechanism for the failed
protein degradation, abnormal accumulation of pathological
hallmarks of AD, including Aβ (which was increased in this
study), and age-related neurodegeneration.
Mutations, altered expression or aberrant functionality of
several metal transporters belonging to the ATP7, ATP13,
TRMPL, and ZnT families have also been implicated in
neurodegenerative disorders (Lovell et al., 2005; Lyubartseva
et al., 2010; Quadri et al., 2012; Yonova-Doing et al., 2012).
Increased ATP13a2 expression has previously been shown to
attenuate lysosomal dysfunction in fibroblasts derived from PD
patients (Dehay et al., 2012a,b). Therefore, it is likely that
downregulation of ATP13a2 in aged O. degus may impair
lysosomal function. Neurodegenerative processes involving
aberrant cellular metal trafficking may be intricately linked at the
molecular level.
While Cu/Fe dysregulation may represent a useful biomarker
for AD, on its own it is not conclusive. We analyzed the
expression of several proteins, including: IRP2, a central regulator
of intracellular iron and copper metabolism, and a downstream
target of IRP2, the IRE-containing gene DMT1, FOS, and ALAS2
in the frontal cortex of O. degus. Alterations in the expression of
regulatory proteins associated with the metabolism and transport
of Cu and Fe suggest that homeostasis of these redox active metals
is dysregulated in O. degus, and contributes to the age-related
changes in the microdistribution of Cu and Fe (Mueller et al.,
2012).
In the brain, Zn is transported by several members of the
ZIP and ZnT family of transporters. A significant reduction in
members of the ZIP family of transporters was observed in our
study. In particular, our results are the first to show an age-
related decline in the expression of ZIP7,8 and 14 in the brain
of aged O. degus. It is likely that the loss of ZIP expression
may stimulate perturbations in the metabolism of other redox-
active metals (Dang et al., 2014; Grubman et al., 2014a,b). Excess
unbound Zn may displace other redox-active transition metals
from metalloproteins, and further promote formation of highly
volatile free-radicals via Fenton chemistry (Wilson et al., 2012).
Increased free Zn may also inhibit protein tyrosine phosphatases
in the endoplasmic reticulum, inhibiting the propagation of “Zn
wave” signals throughout cells, thus impairing pleiotropic cellular
signaling processes important for cellular survival (Taylor et al.,
2012).
Previous studies have reported upregulation of ZnT1,
ZnT3, ZnT4, ZnT5, ZnT6, and ZnT7 protein isoforms in the
hippocampus and neocortex in APP/PS1 mice (Lovell et al.,
2005; Smith et al., 2006; Zhang et al., 2010). Similarly, we have
shown that ZnT1, ZnT3, ZnT4, ZnT6, and ZnT7 are increased
with age. On the other hand, a previous study showing that
ZnT3 mRNA and protein levels are reduced in the human
AD brain (Beyer et al., 2009). Two earlier studies have shown
that ZnT1 is decreased significantly in the hippocampus of
subjects with MCI (a stage from which 30% progress to
develop dementia) and pre-clinical AD (PCAD; where subjects
have no overt clinical manifestations of AD but pathology is
revealed post-mortem) (Lovell et al., 2005), as well as in AD.
Moreover, while ZnT4 and ZnT6 were elevated in PCAD and
in the hippocampus of AD patients, no significant difference
in levels was reported for either transporter between MCI
and age-matched controls (Lyubartseva et al., 2010). ZnT3 is
the main Zn transport protein and a major contributor to
Zn2+ release from the synaptic cleft to Zn-enriched terminals,
and may also be responsible for the abnormal distribution
of Zn in the brain (Palmiter et al., 1996). Under normal
physiological conditions, the levels of unbound Zn are regulated
by metallothionein, and the endogenous antioxidant enzyme,
SOD. However, under pathological conditions, Zn may remain
unbound over a significant length of time, and may therefore
interact with Aβ and enhance plaque deposition (Bosomworth
et al., 2012).
Little information is known about the functional role of
Zn10 in AD. A recent study has shown that ZnT10 expression
is upregulated in post-mortem AD brain tissue (Bosomworth
et al., 2013). By contrast, our results show that ZnT10 expression
is reduced in the frontal cortex of aged O. degus. Under
physiological conditions, ZnT10 is localized to the Golgi
apparatus, and maybe translocated to the plasma membrane
following an increase in Zn levels leading to a down-regulation
of ZnT10 expression (Bosomworth et al., 2013). Therefore, it is
possible that the increase in Zn may reduce ZnT10 expression
early in disease course as reported in this study. Reduced
expression of ZnT10 may exacerbate AD progression eﬄuxing Zn
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into the extracellular space, and providing Zn ions to facilitate Aβ
deposition and senile plaque formation.
Our current study has utilized LA-ICPMS and neuro-
molecular biology techniques to examine the microdistribution
of redox-active transition metals, and biometal trafficking
pathways in the brain of aging O. degus. Since age is the greatest
risk factor for AD, our present findings provide a rationale for
further utilization of the metallomic approach in research and
drug development to extend lifespan and maintain healthspan.
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